Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Filed by THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-15 06:26:11 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
Not reported
Expenses
$80,000.00
Filing UUID
7a6109f6-3cf5-4ab0-ab64-a16e19c8659a
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

All legislation related to Medicare site of service payment policy changes; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants

BUD · Budget/Appropriations

Issues related to the President's federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.

GOV · Government Issues

Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; Issues relating to clinical trials at FDA and the ability for patients to be able to access trials earlier in their treatment journey;

MED · Medical/Disease Research/Clinical Labs

Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.